glp-1 cardiovascular outcomes news 363. Agonists: Diving into the Data with Dr. Darren McGuire Beyond GLP1: modulating multiple nutrient-stimulated

[DOI] [PubMed] [Google Scholar] 111.Rizvi AA and Rizzo M, The Emerging Role of Dual GLP-1 and GIP Receptor Agonists in Glycemic Management and Cardiovascular Risk Reduction, Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy 15 (2022): 10231030

Compared with basal insulin, both tirzepatide 5 mg and tirzepatide 15 mg were associated with increased odds of discontinuation of study medication due to adverse events (ESM Table 3)

Are you this provider

NICE recommends considering bariatric surgery for adults with a BMI of 40 kg/m or more, or between 35-40 kg/m with significant obesity-related conditions, with expedited consideration for those with recent-onset type 2 diabetes

Trump: U.S